Cross-border trade — 10 things to know on May 19, 2026

1. The Trump-Xi Beijing summit landed May 14–15 — heavy on symbolism, light on substance. CSIS and CFR read it the same way: a "relatively modest step toward stability," with the Busan truce framework holding in place. Tangible takeaways — China commits to buying at least $17 billion of US agricultural goods per year through 2028, with a first concrete order of 200 Boeing aircraft. Structural addition: two new bodies — a "Board of Trade" and a "Board of Investment" — to manage ongoing bilateral economic engagement.

2. Rare earths: named in the US communiqué, absent from China's. The White House readout listed yttrium, scandium, neodymium and indium among the rare-earth shortages China would address. China's official statement did not mention rare earths. The same asymmetry appeared in the October 2025 Busan agreement — the US side accepts verbal understandings as "outcomes," the Chinese side keeps them in working-group files. For supply chains: rare-earth flow verification now hinges on monthly arrival data, not communiqué text.

3. CAPE Phase 1 — the May 12 Eaton report exposed real numbers. As of May 11 at 7am ET: 15,123,221 entries passed CAPE validation; 8,338,081 entries have been liquidated or reliquidated as if IEEPA never landed; estimated refund principal-plus-interest pool sits at roughly $35.46 billion. Treasury began ACH disbursements May 12. CAPE's real pace, 22 days in, has accelerated meaningfully from the April 28 court declaration's 3%-in-stage snapshot.

4. The US-Mexico first formal round opens week of May 25 — six days from today. Mexico's economy ministry is working through 52 US demands; Mexico has put 12 demands back across the table. Topics: rules of origin, critical minerals, §232 steel and aluminum, auto-parts local-content shares. USTR has stated publicly that Mexico is "not 100% compliant" with USMCA — the public-record framing is itself a negotiating lever.

5. The July 1 USMCA trilateral review is "unlikely to conclude by deadline." Per Mexico Business News and multiple law-firm bulletins: July 1 is only the start of the formal review process, not its terminus. The window for a trilateral consensus extends into late 2026. Whether the three sides land a joint statement before the November 10 Busan expiry feeds into the US-China stability arc as well.

6. The US average effective tariff on Chinese-origin goods sits at roughly 31.6% (MFN + §301 + §122). Steel products stack §232 50% on top. Semiconductors hold an initial 0% rate, stepping up June 23, 2027. The gap between the Busan-cited 47% aggregate and the 31.6% base figure reflects HS-chapter coverage differences — 47% is the §232-inclusive blended rate; 31.6% is the base without §232.

7. §232 pharma 100% rate is 73 days from kickoff. Patented drugs and APIs at 100% full-value; Switzerland on the 15% preferential tier; Ireland, India, China, Singapore, Belgium, Denmark, Germany, France, Italy default to the 100% rate. The 17 Annex III companies go live July 31; other pharma companies September 29. Generics and biosimilars remain exempt.

8. CAPE Phase 2 timing remains undisclosed. CBP has stated future phases will cover finally-liquidated entries but has not committed to a calendar. For importers whose IEEPA-paid entries fell outside the 80-day-pre-liquidation window — the bulk of mid-size brokers and retail importers — the waiting period extends through summer at minimum.

9. The forced-labor §301 investigation moves into determination phase after May 8 rebuttal close. Sixty economies, four hearing days. USTR now consolidates the hearing record with written submissions; a directional decision is expected late July to early August. This track's output may publish jointly with the §301 excess-capacity investigation (July 24 action target).

10. The Busan agreement expires November 10 — 175 days from today. The Beijing summit did not use the word "renewal." It created two committee structures. That is a soft renewal — institutionalize the conversation, keep the hard clauses for the November 10 deadline. The downstream milestones haven't moved: July 24 §301 action, July 31 §232 pharma for 17 firms, September 29 §232 pharma full, November 10 Busan decision day. Every cross-border contract and sourcing decision between now and November is being anchored against this date.